JCI Editorial Board
potential first-tier conflicts of interest

Updated February 17, 2023

Go to the JCI's conflict-of-interest policy

AbbVie (A.B. Heimberger)

AccureX (D. Krainc)

Alnylam (A.B. Heimberger)

Aplexis Inc. (P. Ji)

Arvinas (M. Hussain)

AstraZeneca (M. Hussain)

Bayer (M. Hussain)

BioMed Central (H. Perlman)

Boehringer Ingelheim (G.D. Barish)

Calidi Biotherapeutics (M.S. Lesniak)

Caris Life Sciences (A.B. Heimberger)

Cell IDx (E.M. McNally)

Celularity (A.B. Heimberger)

Cytokinetics (E.M. McNally)

Ethicon, Johnson & Johnson (J. Pandolfino)

Genentech (M. Hussain)

Ikaika Therapeutics Inc. (E.M. McNally)

Inomagen Therapeutics (R. Arora)

Intellia Therapeutics (D. Krainc)

Ionis (J. Bass)

Ironwood (J. Pandolfino)

Lakeside Discovery (E.M. McNally)

Leal Therapeutics (D. Krainc)

Leducq Foundation (H. Ardehali)

Lung Healing Technologies (A. Bharat)

Mannin Research Inc. (S.E. Quaggin)

Medtronic (J. Bass, J. Pandolfino)

Michael J. Fox Foundation (D. Krainc)

Neurocrine Biosciences (A.L. George Jr.)

Nfold (S. Eisenbarth)

OrbiMed Advisors (D. Krainc)

PepGen (E.M. McNally)

Pfizer (N.S. Chandel, E.M. McNally)

Praxis Precision Medicines (A.L. George Jr.)

Rafael Pharmaceuticals (N.S. Chandel)

Regeneron (J. Bass)

Tenaya Therapeutics (E.M. McNally)

Tevard Biosciences (A.L. George Jr.)

Thermo Fisher Scientific (J. Bass)

Vanqua Bio (D. Krainc)

Vertex Pharmaceuticals (J. Bass)

Vortex Therapeutics (S.A. Abdulkadir)

WCG Oncology (A.B. Heimberger)

Zoe Biosciences (D.E. Vaughan)